Hiddo Lambers Heerspink

University of Groningen

Netherlands

Research Interests

Explore related searches

Professors in Netherlands

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (20)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Collaborators (15)

Eva Corpeleijn

University Medical Center Groningen

NETHERLANDS

View details

Jennifer Green

Duke University

UNITED STATES

View details

Rajiv Agarwal

Professor of Medicine

Indiana State University

UNITED STATES

View details

Naveed Sattar

Professor of Metabolic Medicine

University of Glasgow

UNITED KINGDOM

View details

Goos Laverman

University of Twente

NETHERLANDS

View details

Pardeep Jhund

University of Glasgow

UNITED KINGDOM

View details

Robert Toto

Professor with Tenure

University of Texas Southwestern Medical Center

UNITED STATES

View details

Henkjan J. Verkade

NETHERLANDS

View details

Wendy McCallum

Assistant Professor of Medicine

Tufts Medical Center

UNITED STATES

View details

Brendon Neuen

The George Institute for Global Health

AUSTRALIA

View details

James Januzzi

UNITED STATES

View details

Adriaan Kooy

Associate Professor

University Medical Center Groningen

NETHERLANDS

View details

Kieran Docherty

University of Glasgow

UNITED KINGDOM

View details

Janet McGill

Professor of Medicine

Washington University in St. Louis

UNITED STATES

View details

Lesley Inker

Professor of Medicine

Tufts Medical Center

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Hiddo Lambers Heerspink

Research Interests

Explore related searches

Contact this professor

Articles (20)

Comparison of radioactive and non-radioactive iothalamate and hippuran to assess kidney function

What are the right endpoints to assess the effectiveness of new treatments for IgAN?

Impact of Baseline GLP-1 Receptor Agonist Use on Albuminuria Reduction and Safety With Simultaneous Initiation of Finerenone and Empagliflozin in Type 2 Diabetes and Chronic Kidney Disease (CONFIDENCE Trial)

Impact of Simultaneous Initiation of Finerenone and Empagliflozin on Urinary Albumin-to-Creatinine Ratio in Asia

Authors' Reply: Tirzepatide and Kidney Protection in Obesity: Unanswered Questions

Comparing CKD populations with T1D and T2D: a perspective based on the FINE-ONE and FIDELITY populations

Effects of Dapagliflozin on Progression of Chronic Kidney Disease According to Different Rates of Pre-Trial Progression

Protein profiles and associated biological pathways among different etiologies of chronic kidney disease: new insights from DAPA-CKD

Efficacy and Safety of Baxdrostat in Participants with CKD and Uncontrolled Hypertension

Decline in glomerular filtration rate as an endpoint in heart failure clinical trials: challenges and solutions

Estimated lifetime benefit of novel pharmacological therapies in patients with type 2 diabetes and chronic kidney disease: A joint analysis of randomized controlled clinical trials

Cardiorenal Biomarkers, Canagliflozin, and Outcomes in Diabetic Kidney Disease: The CREDENCE Trial

Effects of Tirzepatide Versus Insulin Glargine on Cystatin C–Based Kidney Function: A SURPASS-4 Post Hoc Analysis

Albuminuria and markers for cardiovascular risk in 12-year-olds from the general Dutch population: a cross-sectional study

Derivation and independent validation of kidneyintelX.dkd: A prognostic test for the assessment of diabetic kidney disease progression

Obesity-Related Kidney Disease: Current Understanding and Future Perspectives

Efficacy and safety of zibotentan and dapagliflozin in patients with chronic kidney disease: study design and baseline characteristics of the ZENITH-CKD trial

Diuretic medication and change in fluid retention biomarkers during treatment with the endothelin receptor antagonist atrasentan

Effects of albuminuria‐lowering treatments on inflammation markers: A post hoc analysis from the ROTATE trials

Effects of atrasentan on markers of liver function in patients with type 2 diabetes and chronic kidney disease

Collaborators (15)

Eva Corpeleijn

Jennifer Green

Rajiv Agarwal

Naveed Sattar

Goos Laverman

Pardeep Jhund

Robert Toto

Henkjan J. Verkade

Wendy McCallum

Brendon Neuen

James Januzzi

Adriaan Kooy

Kieran Docherty

Janet McGill

Lesley Inker

Make your next move.